跳至主要内容
临床试验/NCT05596032
NCT05596032已完成不适用

Prospective Field Study to Validate the Diagnostic Performance of the IVD CAPSULE COVID-19-NP Test for the Detection of SARS-CoV-2 on abioSCOPE®

Abionic SA1 个研究点 分布在 1 个国家目标入组 440 人开始时间: 2022年10月23日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Abionic SA
入组人数
440
试验地点
1
主要终点
Diagnostic performance of the IVD CAPSULE COVID-19-NP antigenic test

研究概览

简要总结

The purpose of the study is to conduct a prospective evaluation of the diagnostic performance of the IVD CAPSULE COVID-19-NP test for antigenic determination of SARS-CoV-2 virus on the abioSCOPE® instrument.

The objective of the clinical study is to demonstrate that the IVD CAPSULE COVID-19-NP test:

  1. shows sensitivity:
  • ≥ 80% when testing unselected symptomatic participants within the first seven days of symptom onset or asymptomatic participants when diagnosis is confirmed by RT-PCR; Or
  • ≥ 90% for subjects with Ct ≤ 25.
  1. show ≥ 98% specificity.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • provide valid informed consent before taking the tests;
  • in the case of symptomatic patients, be tested within the first seven days after the onset of symptoms.
  • Male or female, aged equal to or older than 18 years of age.

排除标准

  • Symptomatic participants who take the test after seven days after the onset of symptoms are excluded from the study

结局指标

主要结局

Diagnostic performance of the IVD CAPSULE COVID-19-NP antigenic test

时间窗: through study completion, an average of 1 month

The purpose of this work is to carry out a prospective evaluation of the diagnostic performance of the IVD CAPSULE COVID-19-NP test for the antigenic determination of the SARS-CoV-2 virus on the abioSCOPE instrument.

次要结局

未报告次要终点

研究者

发起方
Abionic SA
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验